Archive

Neovasc Announces Results for the Third Quarter of 2017

NASDAQ, TSX: NVCN VANCOUVER, Nov. 14, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced financial results for the third quarter ended September 30, 2017 (all figures in U.S. dollars unless otherwise indicated). "From a product perspective, our two lead devices continue to...

Read More

Neovasc to Host Third Quarter 2017 Conference Call

NASDAQ, TSX: NVCN VANCOUVER, Nov. 10, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that it will release its financial results for the third quarter 2017 on Tuesday, November 14, 2017, after markets close. The Company will subsequently hold a conference call...

Read More

Neovasc Announces US$65 Million Underwritten Offering of Units Consisting of Common Shares and Warrants To Purchase Common Shares and Concurrent Private Placement of Notes and Warrants

NASDAQ, TSX: NVCN VANCOUVER, Nov. 9, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq: NVCN) today announced that it has priced an underwritten offering of 6,609,588 Series A units (the "Series A Units") of Neovasc and 19,066,780 Series B units (the "Series B Units"...

Read More

Neovasc Receives FDA Approval to Initiate Pivotal Reducer Trial

NASDAQ, TSX: NVCN VANCOUVER, Nov. 6, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced that it has received approval of the U.S. Food and Drug Administration ("FDA") to initiate the COSIRA-II IDE pivotal clinical trial.  The trial's purpose will be to...

Read More

Neovasc Provides Litigation Update

NASDAQ, TSX: NVCN VANCOUVER, Nov. 3, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) reported today that the United States Court of Appeals for the Federal Circuit affirmed the judgment of the United States District Court for the District of Massachusetts in the case of CardiAQ Valve Tech.,...

Read More

Neovasc Provides Tiara™ Clinical Update

NASDAQ, TSX: NVCN VANCOUVER, Sept. 12, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today provided an update on the study progress and clinical performance of the TiaraTM valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation ("MR"),...

Read More

Neovasc’s Reducer System Reviewed in European Heart Journal

Review serves to update clinicians as to current evidence and future perspectives on the optimal utilization of this innovative technology NASDAQ, TSX: NVCN VANCOUVER, Sept. 5, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the European Heart Journal published a clinical...

Read More